Literature DB >> 21122571

Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.

O Pozler1, J Chládek, J Malý, M Hroch, P Dědek, M Beránek, P Krásničanová.   

Abstract

BACKGROUND AND AIM: Azathioprine (AZA) has a slow onset of action in treatment of pediatric inflammatory bowel disease (IBD). It is anticipated, that this delay correlates to the kinetics of 6-thioguanine nucleotides (6-TGN) accumulation. The aim of this study was to evaluate the time to steady state of 6-TGN concentration in red blood cells.
METHODS: The inclusion criteria were: a) age 0-19 years b) IBD diagnosis c) AZA treatment initiation. High performance liquid chromatography was used for the 6-TGN analysis. Concentrations of metabolites were studied in weeks 0, 1, 2, 5, and 8 after beginning of treatment.
RESULTS: The inclusion criteria were matched to 18 patients with IBD. The median time to steady state of 6-TGN was 55.3 days. The mean 6-TGN concentration at the steady state achieved 326 (SD 154) pmol/8.108 erythrocytes. High erythrocyte TPMT activity corresponds to the low steady state 6-TGN concentration and vice versa. This correlation reached statistical significance (p<0.01) for the dose expressed in mg per square meter of body surface area.
CONCLUSION: The time to steady state of 6-TGN erythrocyte concentration is significantly shorter than would expected according to clinical observation describe earlier.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122571     DOI: 10.1016/j.crohns.2010.06.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

1.  Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.

Authors:  Kristyna Pospisilova; Jitka Siroka; Eva Karaskova; Ondrej Hradsky; Tereza Lerchova; Kristyna Zarubova; Ivana Copova; Lucie Gonsorcikova; Maria Velganova-Veghova; Irena Francova; Lubor Urbanek; Milos Geryk; Vladimir Mihal; Jiri Bronsky
Journal:  Paediatr Drugs       Date:  2021-03-11       Impact factor: 3.022

Review 2.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

3.  Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.

Authors:  Y Tanaka; A Manabe; H Fukushima; R Suzuki; H Nakadate; K Kondoh; K Nakamura; K Koh; T Fukushima; M Tsuchida; K Koike; N Kiyokawa; E Noguchi; R Sumazaki; T Komiyama
Journal:  Pharmacogenomics J       Date:  2014-11-18       Impact factor: 3.550

4.  Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.

Authors:  Rikke B Holmstrøm; Ditte V Mogensen; Jørn Brynskov; Mark A Ainsworth; Jacob Nersting; Kjeld Schmiegelow; Casper Steenholdt
Journal:  Dig Dis Sci       Date:  2018-03-21       Impact factor: 3.199

5.  Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.

Authors:  Namita Singh; Marla C Dubinsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-01

Review 6.  Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.

Authors:  Anastasia Konidari; Antonios Anagnostopoulos; Laura J Bonnett; Munir Pirmohamed; Wael El-Matary
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.